Knight Therapeutics (TSE:GUD) Shares Up 1.3% – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD)’s stock price shot up 1.3% on Wednesday . The company traded as high as C$8.42 and last traded at C$8.31. 51,439 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 94,851 shares. The stock had previously closed at C$8.20.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$9.50 price objective on shares of Knight Therapeutics and gave the company a “buy” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of C$9.50.

Knight Therapeutics Stock Up 1.8%

The company has a debt-to-equity ratio of 8.86, a current ratio of 2.32 and a quick ratio of 1.79. The firm’s 50-day moving average is C$7.85 and its 200 day moving average is C$6.70. The stock has a market cap of C$845.32 million, a price-to-earnings ratio of 143.50, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.14.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a net margin of 1.10% and a return on equity of 0.73%. The firm had revenue of C$147.59 million during the quarter. Sell-side analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.